TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* ALL de novo high-risk criteria~* Age 15-55 years (55-60 years patients will be included at the discretion of the medical team that will attend)~* No prior treatment, except Emergency leukapheresis Emergency treatment of hyperleukocytosis with hydroxyurea Urgent cranial irradiation (one dose) for CNS leukostasis Mediastinal irradiation for urgent superior vena cava syndrome~* General condition suitable scale (ECOG 0-2), or\> 2 if due to ALL~* Negative pregnancy test for women of childbearing age~* Written informed consent because, although the protocol does not include the use of investigational drugs, biological samples sent there for them~Exclusion Criteria:~* L3 type ALL or mature phenotype B (sIg +) or cytogenetic abnormalities characteristic of mature B-ALL (t (8; 14), t (2, 8), t (8; 22)). For these patients is available BURKIMAB protocol.~* LAL Ph (BCR-ABL) positive. For these patients have the protocol ALL-Ph-08 (if under 55) or LALOPh (if over 55).~* Lymphoid blast crisis of chronic myeloid leukemia~* Biphenotypic acute leukemia or bilinear according to the criteria of EGIL group~* Undifferentiated acute leukemias~* Patients with a history of coronary artery disease, valvular or hypertensive heart disease, contraindicating the use of anthracyclines~* Patients with chronic phase of activity~* Patients with severe chronic respiratory failure~* Kidney failure due to ALL~* Serious neurological disorder not due to the LAL~* History of pancreatitis~* Pregnancy or breastfeeding~* Mental or psychiatric illness preventing informed consent is given for sending samples or properly follow the study~* General condition affected, not attributable to the ALL

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud (Type: None): Vincristine in induction:5 mg/m2 i.v. days 1, 8, 15 and 22 in induction phase Daunorubicin in induction 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone in induction: 60 mg/m2/ day, i.v. o p.o., days 1 to 14; 30 mg/m2/day, i.v. o p.o., days 15 to 21; 15 mg/m2/day i.v. o p.o., days 21 to 28 Metotrexato 12 mg days 1 and 22 (intrathecal) Cytarabine (ARA-C): 30 mg days 1 and 22 (intrathecal) Hydrocortisone: 20 mg days 1 and 22 (intrathecal) Idarubicin-induction 2 12 mg/m2, i.v., days 1, 3 and 5 Fludarabine in induction-2: Fludarabine 30 mg/m2, i.v., days, 1 to 5

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Care Partners: Web-based Support for Caregivers of Veterans Undergoing Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18 years or older, cognitively intact, English-speaking, able to hear, and own a telephone.~* Patients can have any solid tumor.~* Patients must be initiating IV cytotoxic chemotherapy and, if recurrent, have experienced a 1 month treatment free interval.~* Caregivers must be 18 years or older, cognitively intact, English-speaking, and able to hear/speak for interviews.~* Caregivers must have access to a telephone and computer with high speed internet access.~Exclusion Criteria:~* Patients will be excluded if they have a hematologic malignancy or are receiving bone marrow transplantation.~* Patients and caregivers will be excluded if they have an untreated serious mental illness or cognitive impairment, are institutionalized or enrolled in hospice (prior to trial), or plan on not receiving all care from VA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CarePartners+ (Type: EXPERIMENTAL): Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive the intervention (Intervention = access to a caregiver Web site that updates them on patient's symptoms and provides tailored problem solving advice).
- CarePartners- (Type: NO_INTERVENTION): Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive nothing (i.e. no access to the caregiver website, or 'intervention').

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable angina pectoris who had a positive exercise treadmill test according to the American College of Cardiology Foundation and the American Heart Association guidelines~Exclusion Criteria:~* Acute coronary syndrome~* Coronary revascularization within the past 3 months~* Asthma or chronic obstructive lung disease~* Bradycardia (heart rate \< 55 beat/min)~* History of severe adverse reaction to beta-blockers~* Symptomatic arrhythmia requiring anti-arrhythmia therapy~* Heart failure~* Severe renal or hepatic failure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Carvedilol (Type: EXPERIMENTAL): Carvedilol 25 mg twice a day
- Atenolol (Type: ACTIVE_COMPARATOR): Atenolol 50 mg twice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in acute treatment for binge-eating disorder and obesity;~* Did not have a positive response to acute treatment;~* Available for the duration of the treatment and follow-up (20 months);~* Read, comprehend, and write English at a sufficient level to complete study-related materials; and~* Able to travel to study location (New Haven, CT) for weekly visits.~Exclusion Criteria:~* Currently taking anti-depressant medications;~* Currently taking opioid pain medications or drugs;~* Currently taking medications that influence eating/weight;~* History of seizures;~* Current substance use disorder or other severe psychiatric disturbance (e.g., suicidality);~* Past or current anorexia nervosa, bulimia nervosa;~* Pregnant or breastfeeding;~* Medical status judged by study physician as contraindication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cognitive-Behavioral Therapy (CBT) (Type: EXPERIMENTAL): CBT is a specialist focal treatment with three overlapping phases. (1) Establishing a collaborative therapeutic relationship while focusing on educating patients about the nature of binge eating and factors thought to maintain the problem. Specific behavioral strategies (e.g., self-monitoring) are used to help patients identify problematic eating behaviors while establishing a normal structured eating pattern. (2) Integrating cognitive restructuring procedures, focusing on helping patients learn to identify and challenge maladaptive cognitions regarding eating and weight/shape and thoughts that trigger binge eating. (3) Maintaining change and preventing relapse.
- Naltrexone/bupropion (NB) (on-going from acute stage) (Type: ACTIVE_COMPARATOR): Participants will continue acute blinded pharmacotherapy (consisting of either naltrexone/bupropion combination or placebo), but without added cognitive-behavioral therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* moderate to severe papulopustular rosacea defined clinically using the grading system of Wilkin et al. (2004) as having at least ten lesions (either papules or pustules) on face at time of enrollment~* age 18 years or greater willing and able to understand and sign informed consent form~Exclusion Criteria:~* known hypersensitivity to secukinumab~* topical or oral anti-rosacea medication usage for 28 days prior to enrollment~* active Crohn's disease, as secukinumab may exacerbate this disease~* active infection including tuberculosis, hepatitis B or C, human immunodeficiency virus~* participants with latent tuberculosis will need to have treatment initiated prior to starting study drug~* pregnant or lactating~* active and/or uncontrolled medical conditions that may interfere with study procedures or obscure rosacea assessment such as cutaneous lupus~* use of retinoids within past 3 months of enrollment~* use of antibiotics within 4 weeks of enrollment~* use of light based or laser treatment to face within 8 weeks of enrollment~* use of topical or systemic steroids within 4 weeks of enrollment~* acne conglobate, acne fulminans, chloracne, severe acne requiring systemic treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab arm (Type: EXPERIMENTAL): Participants receive secukinumab (7 doses over a 16-week study period).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion criteria:~1. Clinical and histologically confirmed giant globulinemia Fahrenheit (WM Ii International Working Group Standards, IWWM-2, 2003) (Owen et al., 2003)~2. At least one treatment indication is met (7th WM International Working Group standards, IWWM-7) (Dimopoulos et al., 2014)~3. With the lowest serum IgM value \>2 times ULN as the efficacy evaluation index~4. ECOG physical strength score 0-2~5. Voluntary written informed consent prior to trial screening.~Key Exclusion Criteria:~1. Present or prior history of other malignant neoplasms, unless radical treatment has been performed and there is no evidence of recurrence or metastasis in the last 5 years~2. Amyloidosis and central nervous system (CNS) involvement caused by WM~3. Demonstrate disease transformation~4. Patients who had received autologous stem cell transplantation within the previous 6 months~5. A history of organ transplantation or allogeneic bone marrow transplantation~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ICP-022 (Type: EXPERIMENTAL): Subjects will take ICP-022 150mg once daily (QD).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with non-myeloid malignancy~* At least 12 additional weeks of cyclic cytotoxic chemotherapy anticipated regardless of schedule~* Hemoglobin concentration less than 11.0 g/dL within 24 hours before randomization~* Adequate serum folate and vitamin B12~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2~* Of legal age at the time written informed consent is obtained~Exclusion Criteria:~* Known history of seizure disorder~* Known primary hematologic disorder causing anemia other than non-myeloid malignancies~* Unstable/uncontrolled cardiac condition~* Clinically significant inflammatory disease~* Other diagnoses not related to the cancer which can cause anemia~* Inadequate renal and liver function~* Iron deficiency~* Known positive test for HIV infection~* Previously suspected of or confirmed to have neutralizing antibodies to rHuEPO~* Received more than 2 red blood cell (RBC) transfusions within 4 weeks of randomization; or any RBC transfusion within 14 days before randomization; or any planned RBC transfusion between randomization and study day 1~* Received any erythropoietic therapy within 4 weeks of study day 1 or any planned erythropoietic therapy between randomization and study day 1~* Other investigational procedures~* Currently enrolled in or has not yet completed at least 30 days since ending other investigational device or drug trial(s), or subject receiving other investigational agent(s)~* Pregnant or breast feeding~* Not using adequate contraceptive precautions~* Previously randomized into this study~* Known hypersensitivity to any products to be administered~* Concerns for subject's compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Darbepoetin alfa - Group A (Type: EXPERIMENTAL): None
- Placebo- Group B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with unstable angina or non-ST elevation myocardial infarction~2. Patients who are planned coronary angiography~3. Age \>18 years, \<75 years~4. Patients who agree to the study protocol~Exclusion Criteria:~1. Recent treatment with clopidogrel or pletaal or glycoprotein IIb/IIIa Rc antagonist~2. Active bleeding (peptic ulcer, trauma or intra-cranial hemorrhage)~3. Allergy to antiplatelet agent~4. Bleeding diasthesis (blood coagulation disorders, uncontrolled severe hypertension, history of severe bleeding)~5. History of drug abuse or alcohol abuse~6. ST elevation myocardial infarction~7. Pregnancy~8. Low platelet count (\< 100,000 /L) or abnormal results of PT or PTT~9. Liver disease ( bilirubin \> 2 mg/dL, AST or ALT \> 100 IU)~10. Renal failure ( Cr \> 2.0 mg/dL)~11. Malignancy~12. Proton pump inhibitor, NSAIDs statin (except atorvastatin)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- original Clopidogrel Bisulfate (Plavix®) (Type: ACTIVE_COMPARATOR): original Clopidogrel Bisulfate (Plavix®) 600mg loading
- generic Clopidogrel Bisulfate (Plavitor®) (Type: EXPERIMENTAL): generic Clopidogrel Bisulfate (Plavitor®) 600mg loading

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female with an intact uterus with lifetime history of 0-4 sexual partners~Exclusion Criteria:~* Prior Human Papillomavirus (HPV) vaccination~* Prior abnormal paps~* History of genital warts

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 23 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): V501
- 2 (Type: PLACEBO_COMPARATOR): Placebo
- 3 (Type: EXPERIMENTAL): HPV 16 Monovalent Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Ocular~* Study eye deemed to be indicated for ranibizumab ITV therapy at the discretion of the retina specialist~Exclusion Criteria:~Concurrent Ocular Conditions~* Patients legally blind in one or both eyes~* History of or any current clinically relevant intraocular inflammation or ocular inflammatory reaction (any grading from trace and greater is excluded), including non-infectious uveitis or uveitis, or sterile inflammatory reaction after the past ITV injections with any agent~* Active disorder of ocular adnexa and skin in the study eye, including ocular surface infections~* History of or any current indication of excessive bleeding and recurrent hemorrhages, including any prior excessive intraocular (including subconjunctival) bleeding or hemorrhages after ITV injection or intraocular procedures~* Uncontrolled intraocular pressure greater than (\>) 25 millimeters of mercury (mmHg) in the study eye (uncontrolled means that it occurs even with intraocular pressure-lowering therapy)~* Use of therapies that are known to be toxic to any ocular tissues within the 6 months prior to enrollment~Prior Ocular Therapies~* Treatment with any ITV injection within the 27 days prior to Day 1~* Any invasive intraocular surgery, prior long-acting therapeutic agent, or ocular drug release device implantation (approved or investigational) in the study eye at any time during the past 3 months~General~* Receipt of any systemic (non-ocular) investigational drug within 3 months prior to Day 1~* Current systemic coagulation or bleeding disorders and history of recurrent hemorrhages~* Intolerance or known reaction to prior biological therapies~* History of other diseases or physical or laboratory examination findings that per the retina specialist represent a contraindication to ranibizumab use in the patient or may represent an unwarranted patient risk.~* Uncontrolled hypertension (systolic \>160 mmHg and/or diastolic \>100 mmHg while sitting)~* Current systemic infectious disease or a therapy for active infectious disease~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab PFS (Type: EXPERIMENTAL): Healthcare professionals (HCPs) will administer ITV injections of ranibizumab 0.5 mg delivered via PFS to enrolled patients (1 injection to each patient) on Day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects can be enrolled when meeting all criteria as below.~  1. Chinese adolescent and adult (male or eligible female) outpatients with the age of \>=12 years~ 2. Confirmative diagnosis of IAR or PER (as definitions from ARIA 2008 and the coming effective Chinese AR management guideline ), by medical history, symptoms, skin prick tests (SPTs)~ 3. Subject must be symptomatic at screening and willing to maintain same environment throughout the study~ 4. Ability to comply with study procedures~ 5. Literate~Exclusion Criteria:~* Subjects should be excluded when meeting one of criteria as below.~  1. Having complications of nasal disease, or vasomotor rhinitis, rhinitis with eosinophilia, or drug rhinitis~ 2. Having complications of bacterial/viral infection of upper respiratory tract~ 3. Having significant systemic diseases~ 4. History of hypersensitivity to steroids and ingredients~ 5. Pregnant women or under lactation~ 6. Patients who started, discontinued or changed dose of desensitization therapy within 30 days before visit 1~ 7. Patients planning to travel outside the region~ 8. Patients judged to be inappropriate by investigators~ 9. Patients who participated in another study within 4 months before screening~ 10. Patients who could not withdraw drugs during screening period or secure withdrawal period until the initiation day of administration, e.g.~      1. allergy medications~     2. other medications that may affect allergic rhinitis or its symptoms~     3. any medications that significantly inhibit CYP3A4, including ritonavir and ketoconazole

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): vehicle placebo nasal spray
- FFNS (Type: EXPERIMENTAL): fluticasone furoate nasal spray

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with proven HIV-1-infection~* No prior exposition to antiretrovirals~* CD4 cell count between 300 and 500/mm3~* Signed written inform consent~Exclusion Criteria:~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete